DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 1650550-25-6, Ag-221 mesylate, Enasidenib mesilate, Enasidenib methanesulfonate, Enasidenib (mesylate), Uf6pc17xav

Molecular Formula

C₂₀H₂₁F₆N₇O₄S

Molecular Weight

569.5 g/mol

InChI Key

ORZHZQZYWXEDDL-UHFFFAOYSA-N

FDA UNII

UF6PC17XAV

Enasidenib Mesylate is the mesylate salt form of enasidenib, an orally available inhibitor of specific mutant forms of the mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits various mutant forms of IDH2, including the IDH2 variants R140Q, R172S, and R172K, which inhibits the formation of 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH2-expressing tumor cells. IDH2, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by blocking differentiation and the production of the oncometabolite 2HG.

1 2D Structure

UNII-UF6PC17XAV

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

methanesulfonic acid;2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol

2.1.2 InChI

InChI=1S/C19H17F6N7O.CH4O3S/c1-17(2,33)9-27-15-30-14(11-4-3-5-12(29-11)18(20,21)22)31-16(32-15)28-10-6-7-26-13(8-10)19(23,24)25;1-5(2,3)4/h3-8,33H,9H2,1-2H3,(H2,26,27,28,30,31,32);1H3,(H,2,3,4)

2.1.3 InChI Key

ORZHZQZYWXEDDL-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC(C)(CNC1=NC(=NC(=N1)C2=NC(=CC=C2)C(F)(F)F)NC3=CC(=NC=C3)C(F)(F)F)O.CS(=O)(=O)O

2.2 Other Identifiers

2.2.1 UNII

UF6PC17XAV

2.3 Synonyms

2.3.1 Depositor-Supplied Synonyms

1. 1650550-25-6

2. Ag-221 Mesylate

3. Enasidenib Mesilate

4. Enasidenib Methanesulfonate

5. Enasidenib (mesylate)

6. Uf6pc17xav

7. Enasidenib Mesylate [usan]

8. Cc-90007

9. 1650550-25-6 (mesylate)

10. Enasidenib Mesylate (usan)

11. 2-propanol, 2-methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)-, Methanesulfonate (1:1)

12. 2-methyl-1-[4-(6-trifluoromethyl-pyridin-2-yl)-6-(2-trifluoromethyl-pyridin-4-ylamino)-[1,3,5]triazin-2-ylamino]-propan-2-ol Mesylate

13. Methanesulfonic Acid;2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol

14. Unii-uf6pc17xav

15. Idhifa (tn)

16. Chembl3989931

17. Enasidenib Mesylate [mi]

18. Schembl16448052

19. Dtxsid501027943

20. Bcp26166

21. Ex-a1972

22. Enasidenib Mesylate [who-dd]

23. Hy-18690a

24. S4929

25. Enasidenib Mesylate; Ag-221 Mesylate

26. At36098

27. Cs-7541

28. Enasidenib Mesylate [orange Book]

29. Ac-31319

30. D11044

31. Q27291054

32. 2-methyl-1-((4-(6-(trifluoromethyl)pyridin-2-yl)- 6-((2-(trifluoromethyl)pyridin-4-yl)amino)-1,3,5-triazin- 2-yl)amino)propan-2-ol Methanesulfonate

2.4 Create Date

2015-02-23

3 Chemical and Physical Properties

Molecular Formula	C₂₀H₂₁F₆N₇O₄S
Molecular Weight	569.5 g/mol
Hydrogen Bond Donor Count	4
Hydrogen Bond Acceptor Count	17
Rotatable Bond Count	6
Exact Mass	569.12799232 g/mol
Monoisotopic Mass	569.12799232 g/mol
Topological Polar Surface Area	172 Å²
Heavy Atom Count	38
Formal Charge	0
Complexity	727
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	2

4 Pharmacology and Biochemistry

4.1 FDA Pharmacological Classification

4.1.1 Pharmacological Classes

Isocitrate Dehydrogenase 2 Inhibitors [MoA]; Isocitrate Dehydrogenase 2 Inhibitor [EPC]

ABOUT THIS PAGE

Find UNII-UF6PC17XAV manufacturers, exporters & distributors on PharmaCompass

UNII-UF6PC17XAV

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

PATENTS & EXCLUSIVITIES

DIGITAL CONTENT

GLOBAL SALES INFORMATION

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

What are you looking for?